{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 42,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and contrast current standards of care with the proposed solution's benefits.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/25",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.26
      },
      "kind": "list",
      "text": "1L: Current SOC: Alectinib; ALK ~3-5% of NSCLC; ~30-40% CNS disease. Opportunity to supplant standard of care with a differentiated profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "322142a6-5e9c-4bc4-8d3a-046bfcae6787",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.36,
        "y": 0.26
      },
      "kind": "list",
      "text": "2L: Current SOC: Lorlatinib; ~50% single mutations; >60% CNS disease. Opportunity to differentiate with deep, durable responses and TRK-sparing profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80be94c4-ade4-4cdc-b7ec-ffc599486e8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.058,
        "y": 0.26
      },
      "kind": "list",
      "text": "3L+: No clear standard of care; ~25-50% compound mutations; >60% CNS disease. Demonstrated activity in heavily-pretreated patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1c8be6f-2461-48a0-a44f-27585e2e11df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.058,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted. Sources: Cortellis Sales and Forecasts, accessed November 2023; Ou and Zhu Lung Cancer 2019; Kris et. al. JAMA 2014; Shaw and Engelman J Clin Onc 2013; Noé et. al. J Thor Onc 2019; Peters et. al. NEJM 2017; Shaw et. al. Lancet Onc 2017; Dagogo-Jack et. al. Clin Cancer Res 2019; Lin J.J. et al., AACR-NCI-EORTC 2023; FDA Package Inserts for alectinib and lorlatinib; Camidge D.R., J Thorac Oncol. 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aaf84305-ce9d-42d6-978b-0d705eb45a29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.65,
        "x": 0.058,
        "y": 0.19
      },
      "kind": "title",
      "text": "Opportunity to both move up the treatment paradigm & grow the market with deep, durable responses",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1682fb79-70e4-4968-b6be-10b07f06e8d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.45,
        "x": 0.058,
        "y": 0.118
      },
      "kind": "title",
      "text": "Potential Best-in-class Profile for ALK+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8be6db31-6dee-45fc-963e-615e57d8e870",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "f3ca178e-f3e5-488c-9003-a208ab4a0446",
      "evidence": "Segmentation by treatment line (3L+, 2L, 1L) to define market opportunity.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}